Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 26 (6), 618-626

New Treatment Options for Delta Virus: Is a Cure in Sight?

Affiliations
Review

New Treatment Options for Delta Virus: Is a Cure in Sight?

Cihan Yurdaydin. J Viral Hepat.

Abstract

Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite delta virus causing the most severe form of chronic viral hepatitis, no other treatments are available. After many years of inactivity, there is now hope for new treatment approaches for delta virus and some are likely to enter clinical practice in the near future. Four new treatment approaches are currently being evaluated in phase 2 studies. These involve the hepatocyte entry inhibitor myrcludex B, the farnesyl transferase inhibitor lonafarnib, the nucleic acid inhibitor REP 2139 Ca and pegylated interferon lambda. Results obtained so far are promising, and phase 3 studies are expected shortly. This review summarizes the available data on the efficacy and safety of these new drugs.

Keywords: chronic hepatitis delta; interferon lambda; lonafarnib; myrcludex B; treatment.

Similar articles

See all similar articles

Cited by 4 articles

LinkOut - more resources

Feedback